Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

Diabetes Research and Clinical Practice
Hans-Ulrich HaeringEMPA-REG EXTEND™ METSU investigators

Abstract

This study investigated the long-term efficacy and safety of empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes mellitus (T2DM). Of 666 patients treated with empagliflozin 10 mg, empagliflozin 25 mg or placebo once daily for 24 weeks, 472 patients (70.9%) were treated in a double-blind extension trial for ≥52 weeks. Pre-specified exploratory endpoints included changes from baseline in HbA(1c), weight and blood pressure at week 76. At week 76, adjusted mean differences versus placebo in change from baseline in HbA(1c) were -0.7% (-8 mmol/mol) with empagliflozin 10 mg or 25 mg (both p<0.001), in weight were -1.8 kg and -1.6 kg with empagliflozin 10 mg and 25 mg, respectively (both p<0.001), and in systolic blood pressure (SBP) were -2.2 mmHg with empagliflozin 10 mg (p=0.021) and -2.1 mmHg with empagliflozin 25 mg (p=0.029). Sensitivity analyses provided consistent results for HbA1c and weight, but showed no significant difference between empagliflozin and placebo in change from baseline in SBP. Adverse events (AEs) were reported in 81.7%, 82.0% and 81.3% of patients on empagliflozin 10 mg, 25 mg and placebo, respectively. Confirmed hypoglycaemic AEs (glucose ≤3.9 mmol/l and/or requiring assi...Continue Reading

References

May 13, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Priscilla L HollanderUNKNOWN CV181013 Investigators
Oct 1, 2011·Diabetes, Obesity & Metabolism·R A DeFronzoS Del Prato
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators

❮ Previous
Next ❯

Citations

Jun 25, 2016·Nature Reviews. Endocrinology·Abd A TahraniClifford J Bailey
Sep 23, 2016·Expert Opinion on Drug Safety·Puneet Gupta, William B White
Mar 10, 2017·Expert Opinion on Pharmacotherapy·André J Scheen
Oct 19, 2017·Postgraduate Medicine·Sebastian Filippas-NtekouanMoses S Elisaf
Nov 12, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·John E AndersonCharles F Shaefer
Sep 28, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Marc EvansCheryl Neslusan
Apr 19, 2019·The Cochrane Database of Systematic Reviews·Kasper S MadsenBianca Hemmingsen
May 7, 2020·Advances in Therapy·Ona Kinduryte SchorlingHristo Iliev
Jul 18, 2018·Clinical Medicine Insights. Endocrinology and Diabetes·Jennifer D Goldman
Jun 28, 2018·Drugs·James E Frampton
Sep 18, 2020·Kidney Research and Clinical Practice·Tae Jung OhUNKNOWN Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Socie
Jan 28, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mutaib M MashraqiSyed Mohd Danish Rizvi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.